This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Fentons Settles Fourth 'isocyanate' Asthma Case Against Same Employer

LONDON, January 17, 2013 /PRNewswire/ --

A fourth occupational asthma claim in three years against the same plastics manufacturing firm has been settled by Fentons Solicitors LLP, after employees developed occupational asthma because they were exposed to the chemical, 'isocyanate'.

John Gibney, a member of the specialist Industrial Disease Claims team at Fentons, said that his client's case was just the latest where an employee of the plastics firm had developed the condition, and said he fears that there may be even more workers who have been affected who have yet to come forward.

"This latest case, which we settled for £10,000, involved a PVC panel maker who has been affected by the isocyanate when a machine he was using had not been fitted with a fumes extractor," said John, a solicitor with Fentons' Manchester office. "Even when the extraction unit was later fitted, his symptoms continued and it transpired that the extractor was inadequate and the filter inside was not cleaned on a regular basis as it should have been. Our client was also not provided with adequate respiratory protection.

"After he was moved to a different department his condition has improved, but his lungs are still not recovered from the exposure."

John explained that whilst isocyanate was commonly used in industry, it could affect the lungs if precautionary measures such as filtering, appropriate respiratory protection and appropriate ventilation were not applied.

"My colleagues in the Industrial Disease team have dealt with a significant number of these cases from across the country in the last few years, but the fact that this is the fourth claimant to have been exposed at the same plastics manufacturing firm is clearly a cause for concern," he said.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs